Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease

Qingjian Wang, William Uisinger, Blake Nichols, Julia Gray, Leon Xu, Todd W Seeley*, Mitch Brenner, Guangjie Guo, Weihua Zhang, Noelynn Oliver, Al Lin, David Yeowell

Abstract

Background: Connective tissue growth factor (CTGF) is widely thought to promote the development of fibrosis in collaboration with transforming growth factor (TGF-β); however, most of the evidence for its involvement comes from correlative and culture-based studies. In this study, the importance of CTGF in tissue fibrosis was directly examined in three murine models of fibrotic disease: a novel model of multiorgan fibrosis induced by repeated intraperitoneal injections of CTGF and TGF-β2; the unilateral ureteral obstruction (UUO) renal fibrosis model; and an intratracheal bleomycin instillation model of pulmonary fibrosis.

Results: Intraperitoneal coadministration of CTGF and TGF-β2 elicited a profound fibrotic response that was inhibited by the human anti-CTGF antibody FG-3019, as indicated by the ability of FG-3019 to ameliorate the histologic signs of fibrosis and reduce the otherwise increased hydroxyproline:proline (Hyp:Pro) ratios by 25% in kidney (P < 0.05), 30% in liver (P < 0.01) and 63% in lung (P < 0.05). Moreover, administration of either cytokine alone failed to elicit a fibrotic response, thus demonstrating that CTGF is both necessary and sufficient to initiate fibrosis in the presence of TGF-β and vice versa. In keeping with this requirement for CTGF function in fibrosis, FG-3019 also reduced the renal Hyp:Pro response up to 20% after UUO (P < 0.05). In bleomycin-injured animals, a similar trend towards a FG-3019 treatment effect was observed (38% reduction in total lung Hyp, P = 0.056). Thus, FG-3019 antibody treatment consistently reduced excessive collagen deposition and the pathologic severity of fibrosis in all models.

Conclusion: Cooperative interactions between CTGF and TGF-β signaling are required to elicit overt tissue fibrosis. This interdependence and the observed anti-fibrotic effects of FG-3019 indicate that anti-CTGF therapy may provide therapeutic benefit in different forms of fibroproliferative disease.

Background

Fibroproliferative diseases, including chronic pulmonary, hepatic, renal and vascular fibrosis, contribute to nearly half of all deaths in the USA[1,2]. These disorders frequently affect multiple organ systems, complicating the elucidation of their underlying pathogenesis and hindering the development of effective treatments. Nevertheless, two secreted factors, transforming growth factor (TGF-β) and connective tissue growth factor (CTGF), are widely regarded as universal mediators of fibrogenesis, although the precise mechanisms that underlie their concerted effects remain unclear [3-8]. Because TGF-β is a potent inducer of CTGF, most models postulate that CTGF acts as a downstream mediator of TGF-β activity, whereas other studies support an interdependent rather than merely sequential relationship between TGF-β and CTGF and their respective profibrotic activities [9-11].

CTGF is a multifunctional heparin-binding glycoprotein that is normally expressed at low levels but dramatically enriched in virtually all fibrotic conditions [8]. Cell-based studies have shown that CTGF regulates multiple processes that contribute to fibrogenesis, including cell proliferation, migration, adhesion, survival and extracellular matrix production; that it does so as both a downstream and cooperative mediator of TGF-β signaling; and that it affects a variety of cell types that participate in the fibrogenic process, regardless of tissue origin, including mesenchymal stem cells, hepatic...
stellite cells, renal podocytes, mesangial cells, parietal and tubular epithelial cells, pulmonary type II alveolar cells, mesothelial cells, vascular smooth muscle cells, endothelial cells, cardiomyocytes, pericytes and fibroblasts [4]. Moreover, correlative studies in diseased human tissues indicate important links between CTGF and TGF-β in a number of fibrotic disease states, including diabetic nephropathy, idiopathic and non-idiopathic pulmonary fibrosis, liver fibrosis, skin fibrosis (including keloids and systemic sclerosis), atherosclerosis, congestive heart failure, pancreatitis and various forms of malignant disease [3,8].

Data from animal models of human disease also support the importance of CTGF and its interactions with TGF-β in fibrosis. The small interfering (si)RNA-mediated knockdown of CTGF, for example, has been shown to suppress fibrotic responses in three models of liver fibrosis [5,12,13] and in a chronic allograft nephropathy model [14]. Similarly, antisense-mediated knockdown of CTGF has been shown to suppress fibrosis or its indicators in models of type 1 and type 2 diabetic nephropathy [15], unilateral ureteral obstruction (UUO) and subtotal (5/6) nephrectomy-induced kidney fibrosis [16,17], chemically induced liver fibrosis [18], hypertrophic scarring after dermal wound repair [19], and capsular scarring and contracture surrounding breast implants [20]. Notably, TGF-β induction was also reduced after siRNA- and antisense-mediated CTGF knockdown in five of six models in which it was examined [5,12,13,15,16,18], thus indicating that CTGF activity directly or indirectly enhances the expression of its own inducer in a positive feedback manner. In addition, the expression of known TGF-β targets was inhibited by antisense CTGF knockdown in the 5/6 nephrectomy model despite concurrent overexpression of a TGF-β transgene, suggesting that CTGF also promotes TGF-β activity in a fibrotic setting [17]. Thus, CTGF may influence both the level and function of TGF-β and like CTGF, the targeted inhibition of TGF-β itself attenuates fibrogenesis in these and other disease models. However, the myriad crucial functions of TGF-β make it unattractive as a direct target for antifibrotic therapy [3].

In the work described here, a novel CTGF and TGF-β synergy model was developed based on the prior observation that simultaneous or serial subcutaneous coadministration of TGF-β3 and CTGF elicited the formation of persistent fibrotic lesions in neonatal mice, whereas administration of either cytokine alone failed to produce any persistent effect [21]. In this study, we extended these findings to a model in which intraperitoneal co-injections of TGF-β2 and recombinant human CTGF produced profound peritoneal fibrosis, abdominal adhesions, and disseminated fibrosis in vital organs, including lung, heart, kidney and liver. As had been shown in the earlier subcutaneous fibrosis model, fibrosis in the intraperitoneal administration model also required the coadministration of both TGF-β and CTGF, thus demonstrating a robust cooperative interaction between these two factors in the genesis and maintenance of a fibrotic response. Furthermore, FG-3019, a fully human recombinant monoclonal antibody against human CTGF, blocked fibrosis in this model and in two additional clinically relevant rodent fibrosis models, the UUO model of kidney fibrosis and the bleomycin model of lung fibrosis, both of which also respond to TGF-β1/Smad-targeted interventions [22-24]. Thus, treatment with a CTGF-blocking antibody reduced the severity of fibrosis in all three models, thereby indicating that anti-CTGF therapy may be clinically beneficial in diverse fibroproliferative diseases.

**Results**

**Production and characterization of FG-3019 monoclonal antibody**

FG-3019, a fully human recombinant DNA-derived CTGF-reactive monoclonal IgG1/κ antibody, was isolated and cloned from genetically engineered mice expressing human immunoglobulin transgenes (Medarex, Princeton, NJ, USA) [25], which had been immunized with recombinant human CTGF. Using engineered CTGF fusion proteins and CTGF proteolysis fragments, FG-3019 binding activity was mapped to the cysteine-rich von Willebrand Factor type C (VWC) domain of CTGF (Figure 1A). Synthetic peptides derived from the VWC domain sequences of CTGF efficiently displaced FG-3019 in competitive CTGF ELISAs, including a peptide corresponding to CTGF amino acids 135-157, suggesting that these sequences participate in the recognition and binding of CTGF by FG-3019. This segment of the CTGF primary sequence is poorly conserved between related CCN family proteins, including NOV and CYR61 but well conserved within CTGF proteins encoded by diverse mammalian species [26]. Indeed, FG-3019 binds CTGF from a variety of mammalian species, including rodents, and radioimmunoassays indicate that it binds human and rat CTGF with Kᵣ values of approximately 0.1 and 0.3 nmol/l, respectively (data not shown). To confirm the specificity of FG-3019 towards CTGF, as opposed to the structurally related CCN proteins CYR61 or NOV, binding of FG-3019 to recombinant proteins was compared by immunoblot analysis; FG-3019 was indeed avidly associated with CTGF, but not with CYR61 or NOV (Figure 1B). This result was also confirmed by ELISA (data not shown).

**Profibrotic effects of TGFβ2 and CTGF coadministration in neonatal mice**

A novel model of multiorgan fibrosis was developed, involving the repeated intraperitoneal injection of
newborn mice with a combination of TGF-β2 and CTGF. Whereas the gross anatomy of control mice treated with vehicle, TGF-β2 or CTGF alone appeared normal, animals treated with both cytokines together exhibited a profound thickening of the abdominal wall and peritoneal membrane (Figure 2A, B). In severe cases, a thickened fibrous membrane covered the surface of almost all the abdominal organs, and fibrous adhesions were readily apparent between adjacent organs or between otherwise free tissues and the abdominal wall. Organ fibrosis was quantitatively scored by comparing the Hyp:Pro ratios within tissues, which is a standard measure of collagen content relative to total organ protein. Hyp:Pro ratios in the kidney, liver, lung and heart were substantially increased after coadministration of TGF-β2 and CTGF, whereas treatment with either cytokine alone did not increase Hyp:Pro ratios relative to vehicle controls (Table 1), thus demonstrating a clear interaction between CTGF and TGF-β in this model. By these measures, Hyp:Pro changes after coadministration of TGF-β2 and CTGF were most dramatic in kidney and liver (increases of 65% and 160%, respectively, over control), with more moderate but significant increases of 34% and 11% being seen in heart and lung, respectively (P < 0.001 in kidney, liver and heart, P < 0.01 in lung). Because the latter tissues lie outside the peritoneal cavity, this significant increase in their relative Hyp:Pro content indicates that the intraperitoneal coadministration of TGF-β2 and CTGF elicited a systemic rather than purely local fibrotic response. The coadministration of CTGF and TGF-β2 was also associated with a 28% reduction in final body weight (mean ± SE 7.62 ± 0.10 g) compared with healthy controls (10.59 ± 0.24 g), which was significant (P < 0.001). In addition, the severe intra-abdominal fibrosis in these animals appeared to be associated with compromised bowel motility, as indicated by increased accumulation of fecal material in their intestines (data not shown).
In animals that received both TGF-β2 and CTGF, simultaneous treatment with FG-3019 resulted in substantial visible suppression of the peritoneal membrane and abdominal cavity fibrotic responses (Figure 2C). Overt intra-abdominal adhesions were not noted in these animals. This qualitative reduction in gross fibrotic effect was accompanied by a 22% improvement in the mean final (day 21) body weight in the FG-3019-treated cohort (9.32 ± 0.32 g) compared with animals that received TGF-β2 and CTGF without FG-3019 treatment (P < 0.001), although the FG-3019 treated animals were still 12% lighter than healthy controls (P < 0.001). FG-3019 treatment also substantially reduced Hyp:Pro ratios in all organs examined. Specifically, the increase in relative Hyp:Pro content (that is, the fibrotic response) elicited by coadministration of TGF-β and CTGF was reduced by 63% in lung (P < 0.05), 25% in kidney (P < 0.05), 30% in liver (P < 0.01) and 15% in heart after FG-3019 treatment (Table 1).

The observation that frank fibrosis only occurred after coadministration of both TGF-β and CTGF, as opposed to either cytokine alone, and that it was attenuated by FG-3019 antibody treatment, was also confirmed by an independent histologic analysis (Comparative Biosciences, Inc., Sunnyvale, CA, USA). Microscopic analysis of stained liver sections revealed multifocal fibrosis of the hepatic capsule in eight of eight animals that received TGF-β2 and CTGF without FG-3019 treatment (P < 0.001), although the FG-3019 treated animals were still 12% lighter than healthy controls (P < 0.001). FG-3019 treatment also substantially reduced Hyp:Pro ratios in all organs examined. Specifically, the increase in relative Hyp:Pro content (that is, the fibrotic response) elicited by coadministration of TGF-β and CTGF was reduced by 63% in lung (P < 0.05), 25% in kidney (P < 0.05), 30% in liver (P < 0.01) and 15% in heart after FG-3019 treatment (Table 1).

The observation that frank fibrosis only occurred after coadministration of both TGF-β and CTGF, as opposed to either cytokine alone, and that it was attenuated by FG-3019 antibody treatment, was also confirmed by an independent histologic analysis (Comparative Biosciences, Inc., Sunnyvale, CA, USA). Microscopic analysis of stained liver sections revealed multifocal fibrosis of the hepatic capsule in eight of eight animals that received both cytokines (Figure 3A, Table 2). In addition, multiple foci of trace or mild parenchymal fibrosis, primarily in periportal liver regions, were present in three animals that received both cytokines. Thus, the response to TGF-β/CTGF coadministration was primarily one of capsular fibrosis with occasional parenchymal involvement. By contrast, histologic evidence of capsular or parenchymal liver fibrosis was entirely absent in all animals that received either CTGF or TGF-β alone, and focal evidence of trace capsular fibrosis without parenchymal fibrosis was seen in only two of eight animals that received FG-3019 (Figure 3B). Thus, the incidence of any degree of fibrosis after dual-cytokine treatment was significantly reduced by CTGF-targeted FG-3019 treatment (Fisher’s exact test, P = 0.007) and analysis of variance by ranks showed that the histologic liver fibrosis severity scores (0 = no fibrosis, 1 = minimal, 2 = mild to mild, 3 = mild and 4 = moderate fibrosis) for animals that received both TGF-β2 and CTGF (median 1.5, range 1 to 4) were significantly higher than for animals that received vehicle, TGF-β2 or CTGF alone (all scores = 0; Dunn’s test, P < 0.001) and that they were significantly reduced by FG-3019 treatment (median 0, range 0 to 1, P < 0.01). Likewise, mild to moderate renal capsular fibrosis was observed in three of eight animals that received both cytokines without FG-3019 treatment (Figure 3C), whereas no evidence of fibrosis was seen in any other animal from any other group, including the FG-3019 treatment group (Figure 3D). Fibrosis of the renal parenchyma was not seen in any animal in this study, nor was inflammation noted in any tissue.

**Effect of CTGF inhibition in a UUO-induced kidney fibrosis model**

Previous studies have demonstrated a direct correlation between CTGF levels and renal pathology in the UUO-induced kidney fibrosis model [16,27]. In the current study, ligated kidneys of vehicle-treated animals were compared with non-ligated control kidneys of the same animals to determine the fibrotic effect of UUO using the standard tissue Hyp:Pro ratio to assess the fibrotic response. In addition, to determine whether disruption of CTGF signaling inhibits the UUO-induced fibrotic response, ligated kidneys of animals treated for 2 weeks with either vehicle or FG-3019 were compared.

In vehicle-treated control animals, UUO induced a clear fibrotic effect, as indicated by a fourfold increase in the mean Hyp:Pro ratio in ligated kidneys compared with non-ligated control kidneys (0.175 ± 0.011 vs. 0.045 ± 0.0005; P < 0.001). The kidneys of animals treated with 10 and 30 mg/kg FG-3019 were significantly protected from UUO-induced fibrosis, as indicated by

| Organ | Control Treatments | TGF-β2 | CTGF | CTGF |
|-------|--------------------|--------|------|------|
| Kidney | 0.057 ± 0.001 | 0.061 ± 0.002 | 0.059 ± 0.001 | 0.094 ± 0.0051 | 0.085 ± 0.0031 |
| Liver | 0.015 ± 0.001 | 0.017 ± 0.001 | 0.016 ± 0.002 | 0.039 ± 0.0031 | 0.032 ± 0.0021 |
| Lung | 0.079 ± 0.002 | 0.078 ± 0.002 | 0.083 ± 0.001 | 0.088 ± 0.0011 | 0.083 ± 0.0021 |
| Heart | 0.041 ± 0.001 | 0.044 ± 0.002 | 0.046 ± 0.002 | 0.055 ± 0.0021 | 0.053 ± 0.0031 |

Data shown represent mean ± SEM, n = 6 to 10.

1 \( P < 0.01 \), 2 \( P < 0.01 \) compared with healthy control group, one way analysis of variance, Fisher’s least significant difference.

3 \( P < 0.05 \), 4 \( P < 0.01 \) compared with transforming growth factor (TGF)-β2 and connective tissue growth factor (CTGF) coadministration group.
reduction of 20% and 15%, respectively, in their induced Hyp:Pro ratios compared with untreated UUO control mice ($P < 0.05$) (Figure 4), respectively. Histologic analysis using trichrome staining revealed interstitial fibrosis, fibroblast proliferation and increased collagen accumulation in all obstructed kidneys regardless of treatment, with a slight but subjective decrease in the amount of fibrosis seen in the 10 mg/kg FG-3019 treatment group (not shown). Increased trichrome staining was associated with the fibroblast proliferation, and was noted in the interstitium of the cortex, the surrounding glomeruli and the medullary regions of all obstructed kidneys. Marked hydronephrosis, characterized by tubular

Table 2 Incidence of histologic liver fibrosis by severity score

| Treatment          | Degree of liver fibrosis (score) | None (0) | Minimal (1) | Minimal to mild (2) | Mild (3) | Moderate (4) |
|--------------------|----------------------------------|----------|-------------|---------------------|----------|--------------|
| Vehicle            |                                  | 9        | 0           | 0                   | 0        | 0            |
| TGFβ2              |                                  | 8        | 0           | 0                   | 0        | 0            |
| CTGF               |                                  | 6        | 0           | 0                   | 0        | 0            |
| TGFβ2 + CTGF       |                                  | 0        | 4           | 2                   | 1        | 1            |
| TGFβ2 + CTGF + FG-3019 |                            | 6        | 2           | 0                   | 0        | 0            |

Values indicate the number of mice with each categorical liver fibrosis score.
dilation and tubular epithelial loss, was also seen throughout the cortex in all obstructed kidneys regardless of treatment. In addition, multifocal lymphocytic infiltrates were commonly observed in the interstitium of obstructed kidneys, particularly in perivascular regions; however, this was also unaffected by treatment.

Effect of FG-3019 in a bleomycin-induced pulmonary fibrosis model

To confirm that CTGF actively contributes to the pathogenesis of pulmonary fibrosis, and that CTGF inhibition may alleviate the pulmonary fibrotic response, the effect of FG-3019 treatment was examined in a bleomycin-induced lung fibrosis model [24,28]. Bleomycin-treated animals were compared with healthy controls to determine the fibrotic effect of pulmonary bleomycin instillation. Bleomycin-treated animals treated for 2 weeks with either vehicle or FG-3019 were further compared, to investigate the importance of CTGF signaling in pulmonary fibrogenesis. Fibrosis in this model was scored by the standard measure of total lung Hyp, which takes into account the variable Pro content in lung, which is often unrelated to changes in total lung collagen content.

In control mice, bleomycin treatment increased mean ± SEM Hyp content to 452 ± 18 μg per lung (n = 6) compared with non-fibrotic saline-treated controls (285 ± 8 μg per lung; n = 10); a significant 59% increase of 167 μg per lung (P < 0.001). Compared with vehicle-treated bleomycin controls, FG-3019 anti-CTGF antibody treatment resulted in a consistent reduction in mean induced lung Hyp content; a 38% reduction in induced fibrosis in the 10 mg/kg FG-3019 treatment group exhibited a trend towards a treatment effect (P = 0.056) (Figure 5).

FG-3019 Plasma Concentration

Circulating FG-3019 antibody levels were measured by ELISA to confirm FG-3019 exposure after intraperitoneal injection in the studies described above. In the bleomycin and UUO studies, mean ± SD FG-3019 plasma concentrations measured 48 hours after the final injection are shown in Figure 5.
FG-3019 dose of 10 mg/kg were 184 ± 45.6 and 216 ± 71.8 μg/mL, respectively. Consistent with the lower daily and cumulative dose delivered in the neonatal TGF-β/CTGF synergy study, the FG-3019 plasma concentration 24 hours after the final 1.84 mg/kg dose was 21.8 ± 11.5 μg/mL.

**Discussion**

Fibrosis, the excessive and persistent formation of scar tissue, is responsible for the morbidity and mortality associated with organ failure in a variety of chronic diseases affecting the lung, kidneys, eyes, heart, liver and skin. CTGF is strongly overexpressed in fibrotic tissue and is directly linked to the chronic fibrotic effects of TGF-β. VEGF, insulin-like growth factor, angiotensin II and other factors. CTGF acts as a cofactor with TGF-β to induce fibroblasts to become myofibroblasts that deposit collagen, ultimately resulting in organ scarring and dysfunction, and in the most severe forms, organ failure and death. Indeed, CTGF levels in tissue, blood or vitreal fluid have been shown to correlate with the degree and severity of fibrosis in many diseases [29]. Examples include diabetic nephropathy, glomerulonephritis and IgA nephropathy (kidney), diabetic retinopathy and advanced macular degeneration (vitreal fluid), cirrhosis, biliary atresia and nonalcoholic steatohepatitis (serum, liver), congestive heart failure (myocardium), and various forms of pulmonary and skin fibrosis (serum, tissue) [5,29-32].

In the studies described here, the anti-CTGF antibody FG-3019 consistently diminished fibrotic responses in a novel model of CTGF and TGF-β synergy, and in previously described acute inflammatory models of lung and kidney fibrosis. Thus, the anti-fibrotic activity of FG-3019 is required in each of these models supports a key role for CTGF in mediating fibrogenesis. Indeed, FG-3019 alleviated the fibrosis associated with acute bleomycin and UUO injury even though the relatively severe nature of these acute injury models may limit the observable treatment benefit. It was not possible to determine from these models the specific nature of the anti-fibrotic effects of FG-3019, and additional studies will be needed to determine whether the FG-3019 action is exerted directly through effects on initial injury and/or early inflammatory response to injury [33]. Nevertheless, the UUO and bleomycin models were chosen because they have been extensively investigated, and because TGF-β and CTGF have each been implicated in their development and progression [16,22-24,28]. Thus, in the lung and kidney fibrosis models, endogenous TGF-β and CTGF were induced [28], and in the CTGF and TGF-β synergy model, recombinant exogenous TGF-β and CTGF were coadministered directly, with the latter approach resulting in profound encapsulating peritoneal sclerosis and systemic multiorgan fibrosis. Thus, each model provides a useful scenario for investigating CTGF/TGF-β cooperativity and the potential clinical utility of antifibrotic agents.

Previous findings indicated that coadministration of CTGF and TGF-β is required for the establishment of a persistent fibrotic effect in skin after subcutaneous administration [21,34-36]. In the current cooperative interaction model, intraperitoneal coadministration of TGF-β2 and CTGF resulted in the development of profound abdominal fibrosis and disseminated fibrosis in extraperitoneal organs, thus indicating induction of a systemic fibrotic response. Notably, induction of fibrosis in this model required concomitant exposure to both TGF-β and CTGF in a manner indicating functional synergy between these two cytokines in the fibrogenic response. These results indicate that CTGF is both necessary and sufficient to initiate fibrosis in the presence of increased TGF-β signaling, and that TGF-β is both necessary and sufficient to elicit fibrosis in the presence of increased CTGF. Because TGF-β is a potent inducer of endogenous CTGF, it is important to consider why the addition of further exogenous CTGF is required for TGF-β to elicit an overt fibrotic response. One possible explanation is that in the presence of pathologic fibrosis, TGF-β is indeed required, but fails to elicit enough endogenous CTGF on its own. This implies that independent pathways of CTGF regulation are also necessary. Moreover, it suggests that a CTGF threshold must be met to initiate or maintain fibrogenesis, and if so, then even partial inhibition of its activity to levels below a crucial threshold should provide anti-fibrotic benefit. Indeed, in the cooperative interaction model, FG-3019 anti-CTGF treatment reduced the overall level of fibrosis observed after CTGF and TGF-β coadministration in liver, kidney and lung. The magnitude of Hyp:Pro changes is influenced by pre-existing collagen content, the presence of less affected sample areas, and potential accumulation of non-collagenous proteins during fibrosis, whereas the histologic fibrosis scores measure the overall microscopic appearance of a tissue, including tissue areas that may be differentially affected, such as capsular or parenchymal regions. Thus, both measures support the qualitative conclusion that CTGF and TGF-β cooperate to promote tissue fibrosis, and that CTGF inhibition can suppress fibrogenesis.

Although the TGF-β/CTGF cooperative interaction model has properties suggestive of broad relevance to fibrotic disease, it may be specifically relevant to the formation of abdominal adhesions after surgery and to peritoneal fibrosis associated with dialysis procedures. Fibrosis in the TGF-β/CTGF cooperative interaction model was associated with profound peritoneal...
adhesions and signs of intestinal obstruction, a common presentation in patients diagnosed with postoperative peritoneal adhesions [37]. Moreover, CTGF mRNA is significantly increased in postoperative adhesions after peritoneal wounding in animal models [38] and in patients undergoing peritoneal dialysis [39]. Thus, it is likely that CTGF and TGF-β contribute to the formation of intra-abdominal adhesions in a cooperative and potentially targetable manner.

Together, these data provide both gain- and loss-of-function evidence that CTGF plays a crucial role in fibrotic tissue injury, because exogenous CTGF was required to initiate a fibrotic response in the presence of increased TGF-β levels, and because treatment with a CTGF-blocking antibody attenuated the fibrotic response in three independent models of pathologic fibrosis. Moreover, with regard to clinical utility, these data support the conclusion that the anti-CTGF monoclonal antibody, FG-3019, may be useful in controlling the progression of renal, pulmonary and hepatic fibrosis in patients with diseases such as diabetic nephropathy, systemic sclerosis or idiopathic pulmonary fibrosis. These results were obtained in studies of relatively limited treatment duration (14-20 days), as required by use of a human antibody in rodents, so that the added benefit of longer duration treatment regimens could not be assessed. In these studies, the optimum dose and regimen for FG-3019 administration was not fully established, and may differ by disease. However, the antifibrotic effects of FG-3019 have been reproduced in other studies, including comparisons where non-immune IgG groups were used [40].

CTGF exhibits a broad spectrum of biological activities, including effects on bone and cartilage development [41], cell adhesion and chemotaxis [42], and angiogenesis [43], none of which were addressed in these experiments. Moreover, fibrotic tissue remodeling also influences other clinically relevant processes, including cancer progression and organ-graft rejection. In addition to its antifibrotic effects, the FG-3019 anti-CTGF antibody used here has also been shown to attenuate tumor growth, metastasis and angiogenesis in mouse models of pancreatic cancer and to attenuate the anchorage-independent growth of CTGF-overexpressing pancreatic cancer cells [44-46]. Thus, taken together, these studies indicate that CTGF is a clinically relevant target in fibrosis and other disease states.

**Methods**

**Animal selection and handling**

Mice (Charles River Laboratories, Inc., Wilmington, MA, USA) were handled according to standards provided in the National Institutes of Health Guide and the Animal Welfare Act and to protocols approved by the Institutional Animal Care and Use Committee.

**UOO kidney fibrosis study**

In total, 40 male Swiss Webster mice (32-35 g) were assigned to one of four groups (10 mice/group). On the first day of dosing, mice received an intraperitoneal dose of vehicle or FG-3019 (10 or 30 mg/kg), and 4 hours later, mice were anesthetized with isoflurane and UUO was performed on the left kidney [22]. The right (unoperated) kidney served as control. Thereafter, mice received vehicle or FG-3019 every other day to give a total of seven doses. Fourteen days after UUO, the surviving mice were anesthetized with isoflurane, blood was collected via the abdominal vein for plasma FG-3019 concentration by ELISA, and both the left and right kidneys were harvested. Mice that survived to the scheduled termination date were examined for successful ureteral ligation. Five mice with unsuccessful ligations (one from the UUO and vehicle group and four from the UUO and 10 mg/kg FG-3019 group) were excluded from analysis. Half of each kidney was processed for histopathologic analysis. The remaining half of each kidney was processed for determination of Hyp and Pro levels.

**Bleomycin-induced lung fibrosis study**

In total, 40 male C57BL/6 mice (23-26 g) were assigned to one of four bleomycin-treated fibrosis groups (10 mice/group) and treated with FG-3019 (3, 10 or 30 mg/kg) or vehicle (control group). On the first dosing day, mice received an intraperitoneal dose of either vehicle or FG-3019, and 2 hours later received an intratracheal instillation of bleomycin (Bristol-Myers Squibb, Princeton, NJ, USA) at a dose of 0.08 U/50 μL/mouse under isoflurane anesthesia [24,47]. An additional non-fibrosis control group of 10 mice received an intratracheal instillation of saline, and was treated with vehicle. Thereafter, mice received vehicle or FG-3019 every other day to give a total of seven doses. During the dosing period, mice were observed daily, and weights were measured approximately three times per week. Animal weights in all bleomycin treatment groups were somewhat reduced versus saline non-bleomycin control, but final weights did not differ significantly between treatment groups. Similarly, bleomycin-associated mortality was similar between groups exposed to this agent. Fourteen days after the bleomycin instillation, the surviving mice were anesthetized with isoflurane. Blood was collected from the abdominal vein and placed in lithium-heparin tubes and spun at 4°C, then the plasma was frozen at -70°C for subsequent determination of FG-3019 concentration. All dissected lung lobes were quickly freed of non-par enchymal tissue, perfused with ice-cold saline, and hydrolyzed in 6 mol/l HCl at 105°C for 22 hours for subsequent whole-lung Hyp determination by high-performance liquid chromatography (HPLC) amino acid analysis. The standard measure of total lung Hyp in this
model controls for the occasional inconsistent distribution of bleomycin injury associated with intratracheal instillation. Owing to the non-uniform nature of local bleomycin injury, histology samples were not collected.

**TGF-β/CTGF synergy study**

Ten pregnant female Balb/c mice were used, with two dams assigned to each of five experimental groups to provide seven to 10 neonates per group. In each group, neonates were treated with up to two cytokines and with vehicle or FG-3019, as follows: no cytokine vehicle treatment control (healthy control; \( n = 10 \) neonates); TGF-β2 and vehicle (\( n = 7 \) neonates); CTGF and vehicle (\( n = 7 \) neonates); TGFB-2 and CTGF and vehicle (\( n = 10 \) neonates); and TGFβ2 and CTGF and FG-3019 (\( n = 8 \) neonates). Mice aged 1 day old received their first intraperitoneal dose of FG-3019 (1.84 mg/kg) or vehicle (both in a volume of 0.05 mL), followed 1 hour later by intraperitoneal administration of recombinant human TGF-β2 (300 μg/kg) and/or CTGF (300 μg/kg) in a volume of 0.05 mL. This dosing regimen continued once daily for 20 consecutive days. Two mice died: one in the CTGF group (on day 10) and one in the group coadministered TGF-β2 and CTGF (on day 21, before scheduled termination). One day after the final FG-3019 dose, surviving mice were weighed and killed after blood collection for determination of plasma FG-3019 concentration. Organs were harvested for histopathologic analysis (kidney and liver) and determination of total Hyp and Pro (kidney, lung, liver and heart).

**Hyp and Pro determination**

Hydroxyproline and proline were determined by the method of Palmerini et al. [48], except that L-azetidine 2-carboxylic acid (Sigma-Aldrich, St Louis, MO, USA) was substituted for 3,4-dehydroproline as an internal standard. Tissues were hydrolyzed in 6M HCl for 22 hours at 105°C. Samples underwent pre-column derivatization with o-phthalaldehyde and then 4-chloro-7-nitrobenzofuran (Sigma-Aldrich) to form fluorescent adducts of proline and hydroxyproline. The fluorescent adducts were separated and determined by reverse-phase HPLC followed by fluorometric detection.

**Histologic analysis**

Tissue sections were independently examined in an unblinded manner by a licensed pathologist (Comparative Biosciences, Inc.). In the dual-cytokine study, tissue sections were stained with hematoxylin and eosin and with trichrome, and a subjective but relative fibrosis severity score from 0 to 4 was assigned for each examined organ as given in Results, with small focal areas of trace fibrosis constituting ‘minimal’ fibrosis, and larger multifocal (that is, non-diffuse) areas of fibroblasts and extracellular matrix accumulation constituting ‘moderate’ fibrosis.

**Test articles**

FG-3019 was cloned, expressed and purified from a recombinant CHO cell line derived for this purpose. For bleomycin and UUO studies, FG-3019 was prepared in a vehicle solution consisting of 25 mmol/l L-histidine and 137 mmol/l sodium chloride, pH 6.0. For the TGF-β and CTGF synergy study, FG-3019 was prepared in phosphate-buffered saline (PBS; Cellgro™, Mediatech, Herndon, VA, USA). E. coli-derived TGF-β2 and baculovirus-derived recombinant human CTGF [49] were also prepared in PBS vehicle.

**Immunologic methods**

Immunoblotting was carried out according to standard western blotting methods. FG-3019 or polyclonal antisera directed against either CYR61 or NOV were each used to determine the relative affinity of antibody preparations towards baculovirus-derived recombinant human CTGF, CYR61 and NOV. Rabbit polyclonal anti-NOV and anti-CYR61 antisera were generous gifts from Drs Maryvonne Laurent (Hôpital St. Antoine; Paris, France) and Ruth Lupu (UC Berkeley; Berkeley, CA, USA), respectively. For determinations of relative FG-3019 exposure, plasma FG-3019 antibody concentrations were determined by a sandwich ELISA using an exon-3 (VWC homology domain) CTGF peptide for capture of FG-3019 followed by detection with goat anti-human IgG linked to alkaline phosphatase.

**Statistical analysis**

Statistical analyses were performed using the Sigma Stat program (SPSS Science, Chicago, IL, USA). Continuous data were analyzed by one-way analysis of variance with the Fisher’s least significant difference test comparing all groups. Ordinal histologic fibrosis scores were analyzed by the non-parametric Kruskal-Wallis statistic with Dunn’s multiple comparison post-hoc tests. The Fisher’s exact test was used to analyze 2 × 2 contingency data for the presence or absence of histologic fibrosis. In the UUO study, Hyp:Pro ratios from uninjured contralateral control kidneys from all groups were pooled with the healthy control group. \( P < 0.05 \) was considered statistically significant, and unless otherwise indicated, within-group distributions are expressed as mean ± SEM.

**Acknowledgements**

We thank K. Lea Sewell and Saniya Fayzullina for their assistance in manuscript preparation, and Mark Sternlicht for key contributions to manuscript editing and supplemental statistical analyses.
Authors’ contributions
Animal studies were designed and performed by QW, GG, BN and WZ, with input, materials and supporting analyses provided by WU, JG, MB, LX and TS. TS coordinated the preparation of the manuscript. NO, AL and DY supervised the studies. All authors read and approved the final manuscript.

Competing interests
All authors are current employees of FibroGen, or were FibroGen employees when the studies were performed.

Received: 9 June 2010 Accepted: 1 February 2011
Published: 1 February 2011

References
1. Kochanek KD, Murphy SL, Anderson RN, Scott C. Deaths: final data for 2002. Natl Vital Stat Rep 2004, 53:1-115.
2. Bitterman PB, Henke CA. Fibroproliferative disorders. Chest 1991, 99:81-845.
3. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J, 2004, 18:816-827.
4. De Winter P, Leoni P, Abraham D. Connective tissue growth factor: Structure-function relationships of a mosaic, multifunctional protein. Growth Factors 2008, 26:80-91.
5. Bigstock DR. Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): From pharmacological inhibition in vitro to targeted siRNA therapy in vivo. J Cell Commun Signal 2009, 3:5-18.
6. Cicha I, Goppelt-Stuhrmann M. Connective tissue growth factor: Context-dependent functions and mechanisms of regulation. Biofactors 2009, 35:200-208.
7. Mason RM. Connective tissue growth factor (CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it? J Cell Commun Signal 2009, 3:95-104.
8. Shi-wen X, Leask A, Abraham D. Regulation and function of connective tissue growth factor (CCN2) in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev 2008, 19:133-144.
9. Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective tissue growth factor (CCN2): a pathogenic factor in diabetic nephropathy. J Cell Commun Signal 2009, 3:5-18.
10. Qi W, Chen X, Twigg S, Zhang Y, Gilbert RE, Kelly DJ, et al. The differential regulation of Smad7 in kidney tubule cells by connective tissue growth factor and transforming growth factor-beta1. Nephrolology (Carlton) 2007, 12:267-274.
11. Wahab NA, Weston BS, Mason RM. Modulation of the TGFbeta1/Smad signaling pathway in mesangial cells by CTGF/CCN2. Exp Cell Res 2005, 307:502-514.
12. George J, Tsutsui M. siRNA-mediated knockdown of connective tissue growth factor prevents N-nitrosodimethylamine-induced hepatic fibrosis in rats. Gene Ther 2007, 1:790-803.
13. Li G, Xie Q, Shi Y, Li D, Zhang M, Jiang S, et al. Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J Gene Med 2006, 8:809-909.
14. Luo GH, Lu YP, Song J, Yang L, Shi YJ, Li YP. Inhibition of connective tissue growth factor by small interfering RNA prevents renal fibrosis in rats undergoing chronic allograft nephropathy. Transplant Proc 2008, 40:2365-2369.
15. Guha M, Xu ZG, Tung D, Lanting L, Natarajan R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J 2007, 21:3355-3368.
16. Yokoi H, Mukoyama M, Nagae T, Mori K, Suganami T, Sawai K, et al. Reduction in connective tissue growth factor by antisense gene therapy ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol 2004, 15:1430-1440.
17. Okada H, Kikuta T, Kobayashi T, Inoue T, Kanno Y, Takigawa M, et al. Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J Am Soc Nephrol 2005, 16:133-143.
18. Uchio K, Graham M, Dean NM, Rosenbaum J, Desmouliere A. Down-regulation of connective tissue growth factor and type I collagen mRNA expression by connective tissue growth factor antisense oligonucleotide during experimental liver fibrosis. Wound Repair Regen 2004, 12:60-66.
19. Sisco M, Kryger ZB, O’Shaughnessy KD, Kim PS, Schultz GS, Ding XZ, et al. Antisense inhibition of connective tissue growth factor (CTGF/CCN2) mRNA limits hypertrophic scarring without affecting wound healing in vivo. Wound Repair Regen 2008, 16:661-673.
20. Mazaheri MK, Schultz GS, Blalock TD, Caffee HH, Chin GA. Role of connective tissue growth factor in breast implant elastomer capsule formation. Ann Plast Surg 2003, 50:263-268.
21. Mori T, Kawara S, Shinozaki M, Hayashi N, Kaiserma T, Igarashi A, et al. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model. J Cell Physiol 1999, 181:153-159.
22. Sato M, Muragaki Y, Saka S, Roberts AB, Osushima A. Targeted disruption of TGF-beta1/33d3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003, 112:1486-1494.
23. Lan HY, Wu W, Tomita N, Huang XR, Li JH, Zhu HJ, et al. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol 2003, 14:1535-1548.
24. Cutroneo KR, White SL, Phan SH, Ehrlich HP. Therapies for bleomycin-induced lung fibrosis through regulation of TGF-beta1 induced collagen gene expression. J Cell Physiol 2007, 211:585-589.
25. Fishwild DM, O’Donnell SL, Bengoechea T, Hudson DI, Hardin F, Bernhard SL, et al. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 1996, 14:845-851.
26. Harding PA, Surveyor GA, Bigstock DR. Characterization of pig connective tissue growth factor (CTGF) cDNA, mRNA and protein from uterine tissue. DNA Seq 1998, 8:385-390.
27. Higgins DF, Lappin DW, Kieran NE, Anders HJ, Watson RW, Strutz F, et al. DNA oligonucleotide microarray technology identifies fisp-12 among other potential fibrogenic genes following murine unilateral ureteral obstruction (UUO): Modulation during epithelial-mesenchymal transition. Kidney Int 2003, 64:2097-2101.
28. Lasiky JA, Ortiz LA, Tontath B, Hoyte GW, Corti M, Athai G, et al. Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. Am J Physiol 1998, 275:L365-L371.
29. Leask A, Paraparum SK, Shi-wen X, Abraham DJ. Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease? J Cell Commun Signal 2009, 3:89-94.
30. Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Fujimoto M, et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol 1996, 106:729-733.
31. Adler SG, Kang SW, Feld S, Cha DR, Barba L, Striker L, et al. Can glomerular mRNAs in human type 1 diabetes be used to predict transition from normoalbuminuria to microalbuminuria? Am J Kidney Dis 2002, 39:184-188.
32. Paradis V, Perlemuter G, Bonvoisit D, Dargere D, Parfait B, Vidaud M, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001, 34:738-744.
33. Maher TM, Wells AU. Last in translation; from animal models of pulmonary fibrosis to human disease. Respirology 2009, 14:915-916.
34. Kawya Y, Neg PS, Endo K, Kondo M, Chugo S, Ishida W, et al. Neutralizing monoclonal antibody to human connective tissue growth factor ameliorates transforming growth factor-beta-induced mouse fibrosis. J Cell Physiol 2008, 216:880-887.
35. Chugo S, Shirasaki F, Kawara S, Inagaki Y, Kimbata T, Inakai M, et al. Connective tissue growth factor causes persistent proalpha2(I) collagen gene expression induced by transforming growth factor-beta1 in a mouse fibrosis model. J Cell Physiol 2005, 203:447-456.
36. Qi W, Twigg S, Chen X, Polhill TS, Poronnik P, Gilbert RE, et al. Integrated actions of transforming growth factor-beta1 and connective tissue growth factor in renal fibrosis. Am J Physiol Renal Physiol 2005, 288:F800-F809.
37. Duron JJ, Silva NJ, du Montcel ST, Berger A, Muscar F, Hennet H, et al. Adhesive postoperative small bowel obstruction: incidence and risk factors of recurrence after surgical treatment: a multicenter prospective study. Ann Surg 2006, 244:750-757.
38. Thaler K, Mack JA, Zhao RH, Berho M, Grotendorst GR, Duncan MR, et al.: Expression of connective tissue growth factor in intra-abdominal adhesions. Dis Colon Rectum 2002, 45:1510-1519.

39. Zamirkalam KH, Stanley JM, Gray J, Olivier N, Faull RJ: Connective tissue growth factor and its regulation in the peritoneal cavity of peritoneal dialysis patients. Kidney Int 2003, 64:331-338.

40. Booth AI, Cseccsits-Smith K, Wood SC, Lu G, Lipson KE, Bishop DK: Connective tissue growth factor promotes fibrosis downstream of TGFbeta and IL-6 in chronic cardiac allograft rejection. Am J Transplant 2010, 10:220-230.

41. Ivkovic S, Yoon BS, Popoff SN, Safadi FF, Libuda DE, Stephenson RC, et al.: Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 2003, 130:2779-2791.

42. Chen CC, Chen N, Lau LF: The angiogenic factors Cyr61 and connective tissue growth factor induce adhesive signaling in primary human skin fibroblasts. J Biol Chem 2001, 276:10443-10452.

43. Shimo T, Nakashima T, Nishida T, Asano M, Kanyama M, Kuboki T, et al.: Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. J Biochem (Tokyo) 1999, 126:137-145.

44. Aikawa T, Gunn J, Spong SM, Klaus SJ, Korc M: Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther 2006, 5:1108-1116.

45. Dornhofer N, Spong S, Bennewith K, Salim A, Klaus S, Kambham N, et al.: Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 2006, 66:5816-5827.

46. Bennewith KL, Huang X, Ham CM, Graves EE, Effer JT, Kambham N, et al.: The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res 2009, 69:775-784.

47. Segarini PR, Nesbitt JE, Li D, Hays LG, Yates JR III, Carmichael DF: The low density lipoprotein receptor-related protein-alpha2-macroglobulin receptor is a receptor for connective tissue growth factor. J Biol Chem 2001, 276:40659-40667.

48. O’Leary JM, Hamilton JM, Deane CM, Valeevy NV, Sandell LL, Downing AK: Solution structure and dynamics of a prototypical chorin-like cysteine-rich repeat (von Willebrand Factor type C module) from collagen IIA. J Biol Chem 2004, 279:53857-53866.

49. Pertal B: NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues. Mol Pathol 2001, 54:57-79.